Observational studyBMC infectious diseases2026
Liver abscesses in Southern Europe: clinical and microbiological characterization of a retrospective cohort.
Observational study in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Abscess That Was Cancer: Pyogenic Liver Abscess as the Initial Manifestation of Hepatocellular Carcinoma in a Noncirrhotic Patient.Case reports in hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLiver abscess is a potentially life-threatening condition and differentiating between pyogenic (PLA) and amoebic liver abscess (ALA) can be challenging. Besides, increasing antimicrobial resistance and the lack of standardized guidelines complicate its management.
methodsWe conducted an observational study of adult individuals diagnosed with liver abscess at Vall d’Hebron University Hospital (Barcelona) from 2016 to 2020. Patients were classified as cryptogenic (CLA) or non-cryptogenic (NCLA) based on presumed pathophysiology. Data on demographics, microbiology, treatment and outcomes were collected. Multivariate logistic regression identified predictors of ALA, recurrence, and mortality.
results145 patients were included. Median age was 71 years; 74% were male. NCLA represented 72% of cases, mainly due to biliary tract disease (65%). Microbiological diagnosis was obtained in 117 (80%) cases, with Enterobacterales present in 75/103 (73%) of PLA. Enterobacterales showed high resistance rates, with amoxicillin-clavulanate resistance of 56% in NCLA vs. 29% in CLA, and to piperacillin-tazobactam 49% vs. 14%, respectively. ALA accounted for 14/40 (35%) of CLA. Migration or recent international travel was the only predictor (OR 11.2, p = 0.01), but 4/14 (29%) had no risk factors. Recurrence occurred in 7/92 (8%) NCLA cases. Thirty-day mortality for pyogenic abscesses was 14/106 (12%). Solid (OR 6.5, p = 0.003) and hematologic malignancies (OR 6.1, p = 0.043) were independently associated with early mortality.
conclusionCLA and NCLA differ significantly in presentation and microbiological isolations with high antimicrobial resistance among NCLA. In CLA cases, amoebic aetiology should be considered, even in the absence of classical risk factors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.